ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 593

Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate

Josef S. Smolen1, Ronald F. van Vollenhoven2, Benjamin A. Wolfe3, Su Chen3, Jessica L. Suboticki3 and Arthur Kavanaugh4, 1Division of Rheumatology, Department of Medicine, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria, 2Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, 3AbbVie Inc., North Chicago, IL, 4Division of Rheumatology, Allergy, and Immunology, University of California – San Diego, La Jolla, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: adalimumab and methotrexate (MTX), Early Rheumatoid Arthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 13, 2016

Session Title: Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  In patients (pts) with early rheumatoid arthritis (RA), conventional synthetic DMARDs (csDMARDs), preferably methotrexate (MTX), are recommended as first line therapy.1,2 For pts who remain in moderate to high disease activity (HDA), despite csDMARDs, TNF inhibitors are a potential treatment option.1 The purpose of this analysis was to evaluate clinical, functional, and radiographic outcomes following the addition of adalimumab (ADA) to a subgroup of MTX insufficient responders (IR) who experienced rapid radiographic progression (RRP) and/or remained in HDA.

Methods:  OPTIMA3 was a 78-week (wk) randomized, double-blind, double-period trial comparing safety and efficacy of ADA+MTX with placebo (PBO)+MTX in early RA pts. This post hoc analysis included pts who received PBO+MTX for 26 wks (Period 1) and did not achieve stable low disease activity [LDA, DAS28(CRP) <3.2] at wks 22 and 26. These MTX-IR pts received open-label (OL) ADA+MTX for a subsequent 52 wks (Period 2) and were categorized at wk 26 by 1) whether they experienced RRP [change from baseline (BL) in modified total Sharp score (mTSS) >1.5] and 2) disease activity [HDA = DAS28(CRP) ≥5.1 or moderate (MDA) = 3.2≤ DAS28(CRP) <5.1]. For each subgroup, BL values and changes from BL in DAS28(CRP), CDAI, SDAI, HAQ-DI, and mTSS were analyzed.

Results:  At wk 26, 348 (75.7%) PBO+MTX pts did not achieve stable LDA and received OL ADA+MTX for up to 52 wks. Among these MTX-IR pts, 64 (18.5%) experienced RRP during Period 1; 111 (31.9%) and 202 (58.0%) were in HDA or MDA, respectively. Pts experiencing RRP had significantly higher mean BL DAS28(CRP), SDAI, and mTSS compared with non-RRP pts (Table). Following ADA addition, mean DAS28(CRP) and SDAI decreased in RRP pts to levels that were comparable with those observed in non-RRP pts; while mean mTSS did not progress further in both groups. MTX-IR pts who remained in HDA, versus those in MDA, had significantly higher mean BL disease activity scores and less clinical and functional improvements at wk 26, indicating that high BL activity may be a predictor of poor response to initial MTX therapy (Table). Importantly, regardless of wk 26 disease activity status, the addition of ADA resulted in a decrease in mean disease activity and HAQ-DI; among pts starting Period 2 in MDA, but not HDA, mean disease activity scores fell below the LDA threshold after 52 wks of OL ADA+MTX therapy.

Conclusion:  The addition of ADA in early RA pts with a poor response to initial MTX therapy led to a reduction in disease activity and prevention of further radiographic progression. Nearly 20% of pts accumulated radiographic damage during the 26 wks of MTX exposure; the identification of unique characteristics within these pts may allow for a differential therapeutic approach to preserve structural integrity. References:

  1. Singh JA, et al., Arthritis Care Res, 2016; 68(1):1-25.
  2. Smolen JS, et al., Ann Rheum Dis, 2014; 73(3):492-509.
  3. Smolen JS, et al., Lancet, 2014; 383:321-32.


Disclosure: J. S. Smolen, AbbVie, 9; R. F. van Vollenhoven, AbbVie, Amgen, BMS, GSK, Pfizer, Roche, UCB, 2,AbbVie, Biotest, BMS, Celgene, Crescendo, GSK, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, Vertex, 5; B. A. Wolfe, AbbVie, 3,AbbVie, 1; S. Chen, AbbVie, 3,AbbVie, 1; J. L. Suboticki, AbbVie, 3,AbbVie, 1; A. Kavanaugh, AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, 9.

To cite this abstract in AMA style:

Smolen JS, van Vollenhoven RF, Wolfe BA, Chen S, Suboticki JL, Kavanaugh A. Adalimumab (HUMIRA) Halts Radiographic Progression and Reduces Disease Activity in Patients with a Poor Initial Response to Methotrexate [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/adalimumab-humira-halts-radiographic-progression-and-reduces-disease-activity-in-patients-with-a-poor-initial-response-to-methotrexate/. Accessed January 24, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adalimumab-humira-halts-radiographic-progression-and-reduces-disease-activity-in-patients-with-a-poor-initial-response-to-methotrexate/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.